癌症治疗开发商Monopar Therapeutics获得"适度购买"评级, 目标价为56美元50元. Monopar Therapeutics, a cancer treatment developer, gets a "Moderate Buy" rating with a $56.50 target price.

Monopar Therapeutics Inc. 是一家开发癌症治疗方法的生物制药公司，已获得分析师的“适度买入”共识，这表明这是一个相当不错的投资机会，但存在一些风险。 Monopar Therapeutics Inc., a biopharmaceutical company developing treatments for cancer, has received a "Moderate Buy" consensus from analysts, indicating a reasonably good investment opportunity with some risk. 该公司的主要产品Validive正在进行高级临床试验,用于治疗口腔癌患者的疾病. The company's lead product, Validive, is in advanced clinical trials for treating a condition in oropharyngeal cancer patients. Monopar 的市值为 2.0563 亿美元，目标价为 56.50 美元。 Monopar has a market cap of $205.63 million and a target price of $56.50.